Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
Status unconfirmed · Phase 1/Phase 2
Conditions studied: Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
In brief
T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.
Key facts
- Study ID
- NCT02785250
- Run by
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- People needed
- 85
- Starts
- 2016-04-01
- Expected to finish
- 2025-05-01
- Last updated by the study team
- 2021-06-18
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Stanford University — Palo Alto, California, United States
- Georgia Cancer Center at Augusta University — Augusta, Georgia, United States
- Lenox Hill Hospital — New York, New York, United States
- Oregon Health & Sciences University, Knight Cancer Institute — Portland, Oregon, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Mary Crowley Cancer Research Center — Dallas, Texas, United States
- Tom Baker Cancer Centre — Calgary, Alberta, Canada
- Princess Margaret Hospital — Toronto, Ontario, Canada
- Centre Hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.